- Home
- IQ vs SLDB Comparison
IQ vs SLDB Comparison
Compare IQ & SLDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IQ | SLDB |
|---|---|---|
| Founded | 2009 | 2013 |
| Country | China | United States |
| Employees | N/A | 121 |
| Industry | Consumer Electronics/Video Chains | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 872.3M | 932.9M |
| IPO Year | 2017 | 2017 |
Fundamental Metrics
Financial Performance| Metric | IQ | SLDB |
|---|---|---|
| Price | $1.01 | $8.79 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 11 |
| Target Price | $2.91 | ★ $16.36 |
| AVG Volume (30 Days) | ★ 9.2M | 885.3K |
| Earning Date | 05-18-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 34.97 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $8,094,000.00 |
| Revenue This Year | $0.28 | N/A |
| Revenue Next Year | $3.54 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.86 | $3.79 |
| 52 Week High | $2.72 | $11.45 |
Technical Indicators
Market Signals| Indicator | IQ | SLDB |
|---|---|---|
| Relative Strength Index (RSI) | 45.59 | 42.20 |
| Support Level | $0.99 | $6.25 |
| Resistance Level | $1.19 | $8.67 |
| Average True Range (ATR) | 0.07 | 0.46 |
| MACD | 0.02 | -0.14 |
| Stochastic Oscillator | 43.18 | 19.61 |
Price Performance
Historical ComparisonAbout IQ iQIYI Inc.
Iqiyi is a leading streaming video-on-demand company in China that generates revenue mostly through a subscription basis. The platform also provides user-generated content to nonpaying users, monetized through ads. The company self-produces much of the subscription content and also generates revenue through content distribution, gaming, and IP licensing. Iqiyi competes directly with Tencent Video, Alibaba's Youku, ByteDance's MangoTV, and Bilibili. The company is 45% and 5% owned by Baidu and Xiaomi, respectively.
About SLDB Solid Biosciences Inc.
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.